Drug safety sciences and the bottleneck in drug development

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 788-790

  Watkins, P B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPARIN; ISONIAZID; TACRINE;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; CLINICAL RESEARCH; COMPARATIVE STUDY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; IMMUNE RESPONSE; LETHALITY; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; METABOLITE; NONHUMAN; PATENT; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SIDE EFFECT; TORSADE DES POINTES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; UNITED STATES;

EID: 79956321804     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.63     Document Type: Review

References (15)

1. Mullard, A. 2010 FDA drug approvals. Nat. Rev. Drug Discov. 10, 82-85 (2011).
2. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
3. Mundy, A. & Dooren, J.C. FDA panel grants Avandia a reprieve. Wall Street Journal (14 July 2010).
4. Rosati, K. Using electronic health information for pharmacovigilance: the promise and the pitfalls. J. Health Life Sci. Law 2, 171, 173-239 (2009).
5. US Food and Drug Administration. This week in FDA history-July 15, 1962 (2009).
6. Salvi, V., Karnad, D.R., Panicker, G.K. & Kothari, S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br. J. Pharmacol. 159, 34-48 (2010).
7. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I. & Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271, 992-998 (1994). (Pubitemid 24099919)
8. Carlson, M.K., Gleason, P. P. & Sen, S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 21, 108-113 (2001). (Pubitemid 32047579)
9. Senior, J.R. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin. Pharmacol. Ther. 85, 331-334 (2009).
10. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation (July 2009).
11. Watkins, P.B., Seligman, P.J., Pears, J.S., Avigan, M.I. & Senior, J.R. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48, 1680-1689 (2008).
12. Watkins, P.B. et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 34, 243-252 (2011).
13. Hoofnagle, J.H. Drug-induced liver injury network (DILIN). Hepatology 40, 773 (2004).
14. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
15. Stevens, J.L. & Baker, T.K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 14, 162-167 (2009).